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Antisense oligonucleotides (ASO) are single-stranded deoxyribonucleic acids that bind to 
mRNA to inhibit the synthesis of proteins that have been associated with the central mechanisms 
of disease development. Due to their gene silencing capabilities, the potential for ASOs as 
therapeutic agents is wide, but many toxicological challenges such as poor membrane 
permeability, low solubility, and rapid degradation by exonucleases must be overcome before 
ASO medications can be reliably utilized.  In order to negate these challenges, the natural sugar-
phosphate backbone of ASO’s, which is responsible for its rapid degradation, will be replaced by 
one that is hydrolytically stable. To do so, synthetic oligonucleotide analogues that lack the 
traditional ribose-phosphate backbone are being developed and will be studied to assess their 





The availability of novel drugs in genetic medicine has the potential to treat 
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, and other rare genetic 
conditions for which there is no current therapy. The majority of approved drugs target the end 
product of gene translation: the proteins involved in the central mechanisms of disease 
development. However, as of recent, research has shifted to focus on biologically active 
molecules that target RNA or DNA as potential therapeutic agents. Among these molecules of 
interest, a new class of synthetic single stranded molecules of nucleic acids, antisense 
oligonucleotides (ASOs), have demonstrated promising experimental results due to their ability 
to target hnRNAs or mRNAs, interfere with mRNA splicing, and arrest gene translation, thus 
reducing or inhibiting target protein expression.1  
 5 
The ability of ASOs to promote a highly specific reduction in the amount of a mRNA 
makes the clinical application of antisense technologies highly attractive. However, natural 
ASOs are inherently unstable due to their phosphodiester-sugar backbones, which quickly get 
degraded in vivo via exonucleases into monomers that have deleterious non-specific binding 
properties.2 As a result, modifying the oligonucleotide backbone to increase nuclease resistance 
has become an important goal in medicinal chemistry research. A variety of modification 
strategies have been reported, such as altering the phosphodiester moiety (for example, 
phosphoramidate, methylphosphonate, and phosphorodiamidate morpholino), changing the 
backbone linkage altogether (as in peptide nucleic acids), and eliminating the target of nucleases, 
the deoxyribose ribose ring (simplified glycol nucleic acid oligonucleotides).3, 4, 5 
Despite containing modified backbones, current ASOs still face many challenges that 
include, but are not limited to, poor membrane permeability, poor potency, non-specific effects, 
rapid degradation by exonucleases, and short-shelf life, making them unacceptable as therapeutic 
drugs.3 To address these issues, a novel synthetic strategy that replaces the traditional ASO sugar 
backbone with an oligomer derived from seven-membered carbon rings has been developed 
(Figure 1).  
 
 
Figure 1. Seven-membered cyclic monomers containing guanine, adenine, cytosine,  















1T R = CH3








Currently, our research aims to synthesize all desirable cyclic monomers.  Once the 
individual bases are made, nuclease-resistant ASOs will be synthesized in one-step from suitable 
monomers using a DNA templated ring opening metathesis polymerization (TROMP, Figure 2).  
Following TROMP, heat will be used to break the hydrogen bonds holding the two strands 
together; the specific product ASO analogue will be extracted and the DNA template will be 
recycled and reused. Further experiments in vitro will be performed to determine and assess the 
stability, binding specificity, and gene suppression effectiveness of the ASO analog. The aim is 
to synthesize stable ASO analogs, making the application of oligonucleotides more efficient as 
systemic drugs.  
 
 






 Reactions were carried out under dry N2 gas. Unless stated otherwise, solvents and 
reagents were used as obtained from commercial suppliers. Dimethylformamide (DMF), 
tetrahydrofuran (THF), toluene, and ether are dried and purified via a SPPS system. NMR 























































Compound 3T (base = thymine).  Sodium hydride (0.305 g, 12.71 mmol), DMF (20 mL), and 
the base thymine (1.07 equivalent of 2) were placed in a two-necked flask and stirred under N2 
gas for 2 h. Allyl glycidyl ether 2 (2.30 mL, 28.8 mmol) dissolved in DMF (60 mL) was then 
added into reaction mixture; the reaction was brought to 110-120 °C and was heated at reflux for 
16 h. The DMF was removed via short-path distillation in vacuo. The product was extracted 
from the remaining solid with ethyl acetate, which was then removed using a rotary evaporator. 
The prodcut was purified via column chromatography (7:3 of hexanes: ethyl acetate); total yield 
was 64%. 1H NMR (400 MHz, CDCl3) d 7.13 (s, 1H); 5.88 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H); 
5.28 (ddd, J = 17.2, 1.8,1.5 Hz, 1H); 5.22 (ddd, J = 10.4, 1.8, 1.2 Hz, 1H); 4.08 (m, 1H); 4.02 
(apparent dt, J = 5.7, 1.3 Hz, 2H); 3.97 (dd, J = 14.3, 3.2, 1H); 3.69 (dd, J = 9.7, 6.0 Hz, 1H); 
3.52 (dd, J = 9.7, 4.4 Hz, 1H); 3.43 (dd, J = 9.7, 6.0 Hz, 1H); 1.89 (s, 1H). 
 
 
Compound 4T. Compound 3T, 3-Bromo-2-methylpropene, Ag2O, and dry DMF were 
placed in a round-bottomed flask and stirred under N2 at room temperature for 16 h. The DMF was 
removed via short-path vacuum distillation, and the crude product was purified via column 





















Compound 7. A flask containing NaH (11 g, 275 mmol) and THF (500 mL) was placed in an ice 
bath; and allyl alcohol (17 mL, 250 mmol) was added dropwise via syringe to the mixture. The 
ice bath was then removed, and the solution was stirred under N2 gas for 2 h. Afterwards, allyl 
glycidyl ether was added to the reaction mixture. The mixture was brought to reflux for 24 h. 
After cooling to room temperature, methylene chloride (500 mL) was added to the solution. This 
mixture was washed with water and the organic extracts were dried (MgSO4), and the solvent 
was removed via rotary evaporation. The crude product was purified via vacuum fractional 
distillation (1 mmHg). Four fractions were collected at different temperature ranges: 0-80° C for 
fraction I, around 80° C for fraction II, 83-115° C for fraction III, and around 115° C for fraction 
IV. Product (16.573 g, 39%) was collected from fraction III and IV. 1H NMR (400 MHz, CDCl3) 
d 5.87 (ddt, J = 17.4, 10.4, 5.9 Hz, 2H); 5.26 (dd, J = 17.6, 1.0, 2H); 5.19 (br d, J = 10.4 Hz, 2H); 
3.99 (d, J = 5.7 H, 4H); 3.92 (m, 1H); 3.51 (dd, J = 10.7, 4.1, 2H); 3.46 (dd, J = 10.7, 6.6 Hz, 
2H). 
 
Compound 8. A ring-closing metathesis (RCM) was attempted to convert Compound 7 
into 8 under a variety of conditions (Table 1 in Results and Discussion).  
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Diethyl-2,2-di-(3-butenyl)malonate (9). Sodium hydride (5.025g, 0.1256 mol) and dry 
DMF (50 mL) were added into a 250 mL round-bottomed flask, which was placed under N2, and 
cooled in an ice bath. Diethylmalonate (16.90 mL, 0.1113 mol) was added dropwise via syringe, 
and the reaction was stirred at room temperature for 30 min. The mixture was cooled in an ice 
bath and bromobutene (11.3 mL, 111.3 mmol) was added dropwise via syringe. The mixture 
continued to stir under N2 at room temperature for 18 h, after which it was cooled in an ice bath.  
Another portion of sodium hydride (5.138g, 128.5 mmol) was added in four parts over 45 min. 
The mixture stirred under N2 while warming from 0 °C to room temperature for 16 h. The 
reaction mixture was then stirred for 72 hours. Sodium hydride (2.096g, 84 mmol) was added 
once more, and the mixture was stirred at room temperature for an hour. Bromobutene (4.40 mL, 
40.7 mmol) was also added dropwise to the mixture once again; the reaction was allowed to 
proceed for 24 h at room temperature. Diethyl ether was then added to the mixture, which was 
then washed with water 3 times with water. The ether layer was dried over MgSO4, filtered, and 
solvent was removed via rotary evaporation, leaving an oil that was filtered through a silica plus 
to yield 26.372 g (88%) of the desired product. 1H NMR (400 MHz, CDCl3) d 5.80 (ddt, J =17.0, 
10.3, 7.2 Hz, 2H); 5.03 (ddt, J = 17.0, 406, 1.9 Hz, 2H); 5.00 (ddt, J = 10.2, 1.9, 1.3 Hz, 2H); 
4.20 (quart, J, 7.2, 4H); 2.08 (apparent t quart, J = 7.2, 1.2 Hz, 4H); 1.90 (m, 4H); 1.26 (t, J = 7.1 











Diethyl 1-cycloheptenedicarboxylate (10). A 2-liter round-bottomed flask containing 
0.75 L of degassed dichloromethane, diethyl-2,2-di-(3-butenyl)malonate (9, 1.015 g, 3.785 
mmol), and G1 catalyst (0.150g, 0.182 mmol) was stirred for 5 d. The solvent was then removed, 
and the crude product was dissolved in hexanes (10 mL) and filtered through silica, which was 
then washed with 10% ethyl acetate/hexanes. After removal of the solvents via rotary 
evaporation, a tan oil was obtained (0.906 g, 99.6% yield). 1H NMR (400 MHz, CDCl3) d 5.67 
(br s, 2H); 4.21 (quart, J = 6.9 Hz, 4H); 2.25 (m, 8H); 1.27 (t, J = 7.0 Hz, 6H). 
 
 
4-Cycloheptene-1-Carboxylic Acid (11). Compound 10 (1.644 g, 6.85 mmol), NaOH 
(1.436g, 35.9mmol), ethanol (5 mL), water (10 mL), and THF (3 mL) were combined in a round-
bottomed flask fitted with a condenser and stir bar. The reaction was brought to reflux under N2 
and kept there for 48 h. Upon cooling to room temperature, water (30 mL) and concentrated HCl 
were added to the reaction until the pH reached 1-2. The mixture was extracted with ether, dried 
with MgSO4, and the solvent removed, leaving a white powder (1.260 g, 100%). A portion of the 
hydrolyzed product (0.213 g, 1.16 mmol) and DMAP (2.5 g, 21 mmol) were suspended in 
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in hexane.  A silica column was run, first using hexanes to pull of decalin, then ethyl acetate to 
elute compound 11 (0.101 g, 62%). 1H NMR (400 MHz, CDCl3) d 5.80 (m, 2H); 2.64 (tt, J = 9,7, 
4.1 Hz, 1H); 2.33 (m, 2H); 2.13 (m, 2H); 2.03 (m, 2H); 1.69 (m, 2H). Lit:7 δ 5.78 (t, 2H, 
HC=CH), 2.6 (m, 1H, H2C-CH-CH2), 2.4 (m, 4H, HC-CH2-CH2), 2.2 (m, 4H, HC=CH-CH2-
CH2). 
 
5-hydroxymethylcycloheptene (12). 4-Cycloheptene-1-carboxylic acid (1.020 g, 6.788 
mmol) and diethyl ether (35 mL) were placed in a round bottom flask equipped with a stir bar, 
condenser, and septum. Lithium aluminum hydride (LAH, 3.0 mL, 7.2 mmol) was added slowly 
over the course of 45 minutes with the reaction producing rapid evolution of H2 gas. The flask 
was swirled intermittently during this addition. Following LAH, the mixture was brought to 
reflux under N2 gas for 3 hours then cooled to 0°C. The cold reaction mixture was stirred 
vigorously and quenched by the dropwise addition of water (6 mL), 15% aqueous sodium 
chloride (6 mL), and water (2.3 mL). The mixture was filtered and 1/5 of the solids was extracted 
by THF with a soxhlet apparatus. The THF and filtrate were treated with 7% NaOH (6 mL) and 
H2O (2 x 6 mL), dried with MgSO4 and filtered. The solvent was removed via rotavap to give a 
pale yellow liquid (0.896 g, 90%). 1H NMR (400 MHz, CDCl3) δ 5.78 (t, 2H, HC=CH), 3.47 (d, 
2H, CH2-OH), 2.1/2.08 (m, 4H, HC-CH2-CH2), 1.77 (m, 1H, CH2-CH-CH2), 1.57 (s, 1H, CH2-
OH). 







Compound 1A. 5-hydroxymethylcycloheptene (320 mg, 2.36 mmol) reacted with 
adenine (401 mg, 2.97 mmol) and triphenylphosphine (PPh3: 760 mg, 2.89 mmol) in a round-
bottomed flask. Under N2 gas, diethyl azodicarboxylate (DEAD: 0.45 mL, 2.85 mmol) was added 
dropwise to the reaction mixture via syringe. The reaction was allowed to proceed for 5 d, after 
which the solvent was removed via rotary evaporation.  Dichloromethane (50 mL) was added, and 
this solution was loaded onto a column (SiO2 and CH2Cl2), from which the product was eluted 
with 2% MeOH/CH2Cl2 (200 mL), followed by 5% MeOH/CH2Cl2 (150 mL). Removal of the 
chromatography solvent gave the desired product (0.170g, 27%). 1H NMR (300 MHz, CDCl3) d 
5.8.40 (s, 1H); 7.78 (s, 1H); 5.81 (m, 2H); 5.64 (br s, 2H); 4.09 (d, J = 7.4 2H); 1.74 (m, 2H); 1.19 





N,N-Dimethyl-1-cylclopenten-1-amine (14). This reaction was done twice, and then 
combined for the distillation Dimethylamine hydrochloride (40.095 g, 491.66 mmol) was 
















NaOH (40.05g, 1.001 mol). The gaseous product of this addition, dimethylamine, passed through 
a drying tube containing NaOH before it was condensed and collected in a two-necked flask 
submerged in a liquid nitrogen/ethyl acetate bath. A slight vacuum was employed to pull off the 
remaining amine in the reaction flask. The liquid dimethylamine was then added to a round 
bottom flask, containing CaCl2 (22.98 g, 207.0 mmol) and dry ether (200 mL). Cyclopentanone 
(8.0 mL, 90.3 mmol) was also added via syringe. The solution was kept under N2 at room 
temperature for 3 d. Afterwards, the solution was filtered and CaCl2 was washed with dry ether 
(200 mL).  
The second reaction was conducted the same way, using 280.180 g (3.436 mol) of 
dimethyamine hydrochloride, 280.230 g (7.006 mol) of NaOH, 160.860 g (1.449 mol) of CaCl2, 
56.0 mL (0.632 mol) of cyclopentanone, and 1.0 L of dry ether. 
The two reaction mixtures were combined and the ether was removed via rotary 
evaporation and the remaining solution was distilled under vacuum via vigreux column (bp 80-
81 oC at 105 mmHg) to give the enamine (35.860 g, 45%).  1H NMR (400 MHz, CDCl3) δ 4.25 
(s, 1H, C=CH-CH2), 2.6 (s, 6H, (CH3)2-N), 2.42 (m, 2H, (N-C)-CH2-CH2), 2.39 (m, 2H, 
(C=CH)-CH2-CH2), 1.9 (m, 2H, CH2-CH2-CH2). 
 
 
Acrolein. The apparatus for acrolein synthesis: a 500 mL three-necked flask (F1) with 
pressure equalizing addition funnel, a 100 mL three-necked flask (F2), and a second 100 mL 
three-necked flask (F3) submerged in ice (Figure 3). Potassium sulfate (20.001 g, 114.8 mmol), 
HO OH




fused potassium bisulfate (102.58, 753.4 mmol) and 30.000 g of glycerol were added to F1 and 
heated to 190-200°C, thus causing the reaction to foam/froth. As F1 was being heated to 190°C, 
Figure 3. Apparatus setup for acrolein synthesis 
F2 was heated to 100-110°C. After the reaction in F1 proceeded for an h or when the frothing 
died down , glycerol (30.309 g) was added dropwise to F1 from the pressure equalizing addition 
funnel. The reaction in F1 continued to run for 4 h before the apparatus was disconnected from 
F2. F2 was then heated for another 1-2 h at 190-200 oC until no more liquid was collecting in F3, 
which contained about 1 g of hydroquinone and which had been cooled in an ice bath. At this 
point, F3 was heated to distill the acrolein into the final flask, which also contained about 1 g of 
hydroquinone as a stabilizer before being disassembled and storage of acrolein occurred. The 
product distilled at 53 to 55 oC and was found to weigh 10.202 g (28%). 1H NMR (400 MHz, 













4-Cycloheptene-1-Carboxylic Acid (11). To a round-bottomed flask equipped with a stir bar, 
placed under nitrogen, and cooled in an ice bath, N,N-Dimethyl-1-cylclopenten-1-amine (16.600 
g, 149.4 mmol) was added. Following the addition of the enamine, acrolein (10.0 mL, 149.7 
mmol) was added dropwise over the course of an h. Upon warming to room temperature, the 
reaction was stirred for 3 h, then anhydrous acetonitrile (37 mL) was added to the mixture. The 
reaction was then cooled using an ice bath, and iodomethane (9.5 mL, 152.6 mmol) was added 
dropwise over the course of 90 min. The resulting solution was then frozen overnight and 
allowed to thaw out in the morning. After thawing/stirring for 2 h, an aqueous solution of 20% 
NaOH (147 mL) was added and the resulting mixture was heated to reflux for 19 h. The brown 
mixture was cooled, and the aqueous layer was extracted with dichloromethane (73 mL). The 
aqueous layer was acidified with concentrated HCl and a yellow-white precipitate formed. The 
precipitate was filtered out and the filtrate was again treated with HCl (3 times), allowing more 
precipitate to form, giving the desired product (7.165g, 32%). 1H NMR (400 MHz, CDCl3) d 
5.80 (m, 2H); 2.64 (tt, J = 9,7, 4.1 Hz, 1H); 2.33 (m, 2H); 2.13 (m, 2H); 2.03 (m, 2H); 1.69 (m, 
2H). Lit:7 δ 5.78 (t, 2H, HC=CH), 2.6 (m, 1H, H2C-CH-CH2), 2.4 (m, 4H, HC-CH2-CH2), 2.2 
(m, 4H, HC=CH-CH2-CH2). 
 
Mesylate 16. The alcohol 12 (0.105 g, 76.2 mmol) and diisopropylethylamine (DIPEA, 0.216 g, 
159 mmol) were added to a 20 mL round-bottomed flask equipped with a stir bar. Dichloro-
methane (5.0 mL) was added, followed by mesyl chloride (0.061 mL, 78.8 mmol). The Flask 








which CH2Cl2 (15 mL) was added. This solution was extracted with saturated aqueous NaHCO3, 
and the aqueous layer was separated and extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give 0.138 g 
(95%) of the product. 1H NMR (400 MHz, CDCl3) d 5.79 (m, 2H); 4.05 (d, J = 6.6 Hz, 2H); 
2.30-2.21 (m, 2H); 2.14-2.03 (m, 2H); 2.04-1.95 (m, 2H); 1.87-1.79 (m, 2H); 1.27-1.17 (m, 2H). 
  
Compound 1T.  A mixture of mesylate 16 (1.26 g, 3.3 mmol), thymine (462 mg, 3.7 mmol), 
dried K2CO3 (1.1 g, 8.0 mmol), and NaI (600 mg, 4.0 mmol) in dry DMF (50 mL) was stirred at 
90°C for 16 h. The reaction mixture was cooled and evaporated; the residue was dissolved in 
ethyl acetate (50 mL). The organic layer was washed with saturated NaHCO3 solution (25 mL) 
and H2O (2 x 20 mL), dried, and evaporated. The crude product was then purified by column 
chromatography, affording 25% yield.  1H NMR (400 MHz, CDCl3) d 6.94 (s, 1H); 5.79 (m, 
2H); 3.55 (d, J = 7.5Hz, 2H); 2.30-2.17 (m, 2H); 2.13-1.99 (m, 3H); 1.78-1.65 (m, 2H); 1.20-
1.06 (m, 2H). 
 
Results and Discussion  
 
The initial monomers: design and attempted synthesis 
 
The initial approach involved the synthesis of the monomers shown in Figure 4.  These 
compounds were chosen because each included an eight-membered ring containing a double 












planned to prepare monomers containing five DNA/RNA bases from a chiral allyl glycidol ether 




Figure 4. Cyclic monomers from Scheme 1 
The exocyclic amino groups of guanine and adenine would be protected as N-
dimethylformamidines, and the amino group of cytosine would be protected via an acetamide. 
Because no protection is needed for thymine, the synthesis of 5T was attempted first. Allyl 
glycidyl ether (2) was initially used as a mixture of enantiomers from a commercial source. If 
this entire synthetic sequence worked, each enantiomer of 2 and subsequent compounds would 





5T (R = Me) or 




















































In the first step, a racemic mixture of ally glycidyl ether 2 was employed for the synthesis 
of compound 3T (base = thymine); the purified product was produced in 75% yield and was 
confirmed to be 3T via 1H NMR spectroscopy. In the second step, 3-bromo-2-methylpropene and 
Ag2O were used to convert compound 3T to 4T, however the attempted synthesis was 
unsuccessful. The desired product may have been lost or stuck to the silica used during column 
chromatography. The synthesis in Scheme 1 was found to be difficult over time due to problems 
with the conversion of 3T to 4T. In addition, the overall strategy would be inefficient and time-
consuming because all five bases were installed in the initial step, causing five different parallel 
pathways to be necessary obtain the five equivalent cyclic monomers; therefore, the approach 
shown in scheme 2 was developed to overcome this limitation, with all monomers prepared from 
the same alcohol 8. 
 




The monomers chosen included a nine-membered ring containing two oxygens and a 
double bond (Figure 5). The strategy was to first synthesize the precursor 8, a nine-membered 
ring substituted with a hydroxymethyl group, via one common pathway for all monomers, then 
via a subsequent reaction, the -OH group would be replaced with any of the five nucleobases, 
yielding the desired cyclic monomer. 
OH













Figure 5. Nine-membered ring monomers to be prepared from 8 
 
 
Thus, to synthesize the cyclic monomers, allyl alcohol reacted with allyl glycidyl ether 
(2) under basic conditions in THF, to yield the symmetrical alcohol 3 (38.5% yield). The product 
structure was confirmed by 1H NMR and mass spectroscopic analysis. Compound 3, under 
condition that promote ring-closing metathesis (RCM), was converted into a nine-membered ring 
containing two oxygens. Trials involving a slight variation of ring-closing conditions, 
summarized in Table 1, were conducted to identify the most efficient and high-yielding synthetic 
method.  
Table 1. Conditions for ring-closing metathesis. 
*G1 and G2 are Grubbs first- and second-generation catalysts, respectively. 
#G1 catalyst was added after 24 h reflux of substrate with Ti(O-ipr)4; mixture was heated at reflux for 40 additional 
minutes. 





Solvent Additive (M) Temp. 
(oC) 
Time 
1 G1 (10 mol %) 0.01 toluene Ti(O-ipr)4 (0.02) 25 96 h 
2 G2 (10 mol %) 0.01 toluene Ti(O-ipr)4 (0.02) 25 48 h 
3 G2 (10 mol %) 0.01 toluene ͞ 25 48 h 
4 G2 (10 mol %) 0.01 toluene Ti(O-ipr)4 (0.02) 110 40 min 
5 G1 (10 mol %) 0.01 toluene ͞ 25 96 h 
6 G2 (10 mol %)† 0.1 toluene  ͞ 110 40 min 
7 G1 (10 mol %)# 0.01 toluene Ti(O-ipr)4 (0.02) 110 24 h 
8 G1 (20 mol %)† 0.0012 CH2Cl2 ͞ 40 48 h  
9 G1 (20 mol %)† 0.0005 CH2Cl2 ͞ 40 72 h 
10 G1 (20 mol %) 0.00058 toluene ͞ 110 40 min 
11 G1 (20 mol %) 0.00029 toluene  Benzoquinone 
(0.00058) 
110 48 h 
 20 
 
After multiple trials and attempts to promote ring-closing, the desired product was 
obtained but this approach was not practical due to difficulty and complexity associated with the 
synthesis of a nine-membered ring, which was identified by previous studies in the chemical. 
literature as one of the hardest ring sizes to synthesize.6 Therefore, the approach shown in 
Scheme 3 was developed in an attempt to utilize a smaller ring that is more readily formed. 
The third synthetic approach: utilizing a 7-membered ring  
The monomers (Figure 6) chosen included a seven-membered ring containing a double 
bond, with the initial route given in Scheme 3. 
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1.  NaOH, EtOH
2.  decalin, heat








62% 90% base = 9-Cl-G or T 
(yields not determined), 
A (27%), or U (0%)
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This route began with the production diethyl-2,2-di-(3-butenyl)malonate from a reaction 
of diethylmalonate, sodium hydride, and 4-bromo-1-butene. The successful production of diethyl-
2,2-di-(3-butenyl)malonate was confirmed by 1H NMR spectroscopy; the yield for this step was 
88%. The diethyl-2,2-di-(3-butenyl)malonate then proceeded to undergo a ring closing metathesis 
quantitatively and hydrolysis/decarboxylation to generate 4-cycloheptene-1-carboxylic acid in 
62% yield. The carboxylic acid was then reduced into 5-hydroxymethylcycloheptene by LAH in a 
yield of 90%. Subjecting 5-hydroxymethylcycloheptene (12) to Mitsunobu reactions employing 
adenine, uracil, thymine, and a precursor to guanine to produce 1A, 1U, 1T, or a precursor to 1G 
gave mixed results. The adenine, thymine, and guanine precursor analogs were successfully 
produced, but the reaction with uracil did not work.  
All compounds were characterized via 1H NMR spectroscopy. Due to limitations in the 
amount of material that could undergo the ring-closing metathesis at one time, the strategy 
Scheme 3 was modified to increase the production of 5-hydroxymethylcycloheptene, which is 






The route in Scheme 4 employs a known synthesis of the desired 5-hydroxymethyl-
cycloheptene (12), the precursor to the addition of the nucleobases. This preparation involved 
adapting the procedure of Marquardt/Newcomb and Adkins/Hartung 7, 8 In addition, the 
Mitsunobu reaction was abandoned in favor of a nucleophilic substitution to attach the 
nucleobases. 
Thus, we began with the synthesis of N,N-Dimethyl-1-cylclopenten-1-amine (45%) from 
a reaction between dimethylamine hydrochloride and sodium hydroxide, followed by 
cyclopentanone. This compound was purified via vacuum distillation. The presence of the 
enamine was confirmed by 1H NMR analysis. The signal at 4.25 ppm indicated the presence of 
the double bond in the cyclopentene, and the signal at 2.6 ppm with an integration of 6 showed 
the presence of the methyl groups attached to a nitrogen.  
N,N-dimethyl-1-cylclopenten-1-amine then reacted with acrolein, iodomethane, and a 
20% aqueous solution of sodium hydroxide to produce 4-cycloheptene-1-carboxylic acid (32%). 
Since acrolein is not commercially available in small quantities, it was synthesized in lab from 
glycerol, potassium sulfate, and potassium bisulfate with a yield of 28%. The structures of 
acrolein and 4-cycloheptene-1-carboxylic acid were confirmed via 1H NMR spectroscopy. The 
aldehyde hydrogen of the acrolein corresponded to the peak at 9.5 ppm, and 4-cycloheptene-1-
carboxylic acid was confirmed by the presence of signals at 5.78, 2.01, 1.99, 1.98/97, and 1.72 
ppm. 
The 4-cycloheptene-1-carboxylic acid was then reduced with lithium aluminium hydride 
to produce 5-hydroxymethylcycloheptene in 90% yield. The product was confirmed via 1H 
NMR, which showed peaks at 5.78, 3.47, and 1.57 ppm, indicating the presence of the double 
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bond on the ring, the methylene group coming off the ring, and the hydrogen in the alcohol 
group, respectively. 
Currently, we are preparing all five of the analogs of 5 via the production of the mesylate 
16, which is then subjected to a nucleophilic substitution reaction to attach the nucleobases. 
Thus, treatment of the alcohol 12 with mesyl chloride and an amine base in dichloromethane has 
provided excellent yield of the mesylate 16.9 This compound has been successfully converted 
into 1T, 1U, and 1A under a variety of conditions.10 We expect to have 1G and 1C in hand soon 




The main goal of this research is to streamline the synthesis of antisense oligonucleotide 
analogues, ultimately making the application of oligonucleotides more effective and efficient as 
systemic drugs. To do so, a novel strategy of replacing the traditional ASO backbone with a 
carbon ring backbone was attempted in four synthetic schemes. Each approach aimed to create a 
cyclic ring that can be attached to each nucleobase, forming cyclic monomers that can be 
polymerized into ASO analogs. 
The first ring system attempted (Scheme 1) may have ultimately been successful; but it 
was abandoned because it required each analog to be synthesized via a separate route. Therefore, 
we sought an approach in which the nucleobases would be attached in the last step to a common 
intermediate, (8, Scheme 2). Unfortunately, the ring-closing metathesis of 7 to form 8 proved to 
be difficult (Table 1), so a completely new ring system was chosen (Figure 6). The initial 
synthesis of these compounds also employed a common intermediate (12, Scheme 3), and it 
successfully produced two analogs (5A and 5-Cl-G, a precursor to 5G).  Although this route 
employed a common intermediate and a high-yielding ring closure, the latter reaction had to be 
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done at extraordinarily low concentration, requiring impractical amounts of solvent. In addition, 
the Mitsunobu reaction done in the last step produced some PPh3-DEAD derived side product 
that co-purified with the product in some instances. As a result, the approach in Scheme 4 was 
developed. This strategy made use of an old literature preparation of 11, and employed an SN2 
reaction in place of the Mitsunobu to attach the nucleobases.   
Once all nucleotides have been synthesized, ring opening metathesis polymerization 
reactions will be performed to synthesize full length ASO strands. Initially, we will study each 
monomer’s conversion to a 20-mer of oligo-5* via a polymerization templated on a 20-mer of its 
complementary oligomer in solution and on a bead (both of which can be obtained 
commercially). Future work includes assessing the strength and specificity of binding of the 
modified oligomers to target sequences of RNA and DNA via melting temperature curves.11 If 
they do bind with specificity for the target sequences, an RNaseH resistance assay will be 
conducted. Longer term goals will involve studying our modified oligonucleotides’ ability to 
silence or suppress gene expression in E. coli cells that have been engineered to express the 
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